Skip to main content
Delfa

← All trials/NCT06993792

Active not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

80

Recruiting sites

-

Estimated enrollment

1,200

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

-

Primary endpoint

•Number of Participants Allocated to Each Study

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06993792
Org study ID27266
Secondary ID2025-521098-14-00
Secondary IDJ2A-MC-GZP1Eli Lilly and Company
Secondary IDJ2A-MC-GZP2Eli Lilly and Company
Secondary IDJ2A-MC-GZPOEli Lilly and Company

Timeline

Milestones

Study start2025-05-15actual
Study first posted2025-05-29actual
Last update posted2026-04-24actual
Primary completion2027-08estimated (month precision)
Study completion2027-08estimated (month precision)

Assets

Investigational agents

Orforglipron

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

There are no specific eligibility criteria for the Master Protocol.

•See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes
•See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint

Number of Participants Allocated to Each Study

Time frame:Baseline to Week 4

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.